BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Olanzapine/samidorphan (Lybalvi) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Olanzapine/samidorphan (Lybalvi)\, from C
 linicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04987229-9210@assetmemo.bio
DTSTAMP:20261121T005031Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olanzapine/samidorphan (Lybalvi): Phase 3 readout est. (NCT04987229
 )
DESCRIPTION:Olanzapine/samidorphan (Lybalvi)\, phase 3\, Schizophrenia.\nSt
 udy: Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/olanzapine-samidorphan-lybalvi#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04987229
URL:https://assetmemo.bio/drug/olanzapine-samidorphan-lybalvi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
